{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:36:43Z","timestamp":1787668603977,"version":"build-2736575974"},"reference-count":77,"publisher":"Elsevier","isbn-type":[{"value":"9780443470387","type":"print"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006920","name":"University of Pennsylvania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/bs.apha.2026.05.003","type":"book-chapter","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:36:29Z","timestamp":1780918589000},"page":"213-251","source":"Crossref","is-referenced-by-count":1,"title":["In vivo transduction of CAR T cells: Pharmacological principles, delivery platforms, and the road to clinical translation"],"prefix":"10.1016","author":[{"given":"Saar I.","family":"Gill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/bs.apha.2026.05.003_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1016\/bs.apha.2026.05.003_bib2","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.ymthe.2020.05.005","article-title":"In vivo generation of CAR T cells selectively in human CD4+ lymphocytes","volume":"28","author":"Agarwal","year":"2020","journal-title":"Molecular Therapy"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.003_bib3","article-title":"In vivo generated human CAR T cells eradicate tumor cells","volume":"9","author":"Agarwal","year":"2021","journal-title":"Oncoimmunology"},{"issue":"9","key":"10.1016\/bs.apha.2026.05.003_bib4","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1182\/blood-2013-11-540641","article-title":"Mystery solved: VSV-G-LVs do not allow efficient gene transfer into unstimulated T cells, B cells, and HSCs because they lack the LDL receptor","volume":"123","author":"Amirache","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/bs.apha.2026.05.003_bib5","first-page":"812","article-title":"In vivo co-engineering of T and NK cells using CD7-targeted lentiviral vectors","volume":"31","author":"Andorko","year":"2025","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.apha.2026.05.003_bib6","first-page":"5473","article-title":"T cell-specific promoter elements for restricting off-target CAR expression in in vivo gene delivery","volume":"41","author":"Appelbaum","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1016\/bs.apha.2026.05.003_bib7","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1038\/nm.2964","article-title":"SAMHD1 restricts HIV-1 infection in resting CD4+ T cells","volume":"18","author":"Baldauf","year":"2012","journal-title":"Nature Medicine"},{"issue":"5891","key":"10.1016\/bs.apha.2026.05.003_bib8","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science (New York, N. Y.)"},{"issue":"6","key":"10.1016\/bs.apha.2026.05.003_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005641","article-title":"Receptor-targeted Nipah virus glycoproteins improve cell-type selective gene delivery and reveal a preference for membrane-proximal cell attachment","volume":"12","author":"Bender","year":"2016","journal-title":"PLoS Pathogens"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.003_bib10","first-page":"99","article-title":"Selective mRNA delivery to T cells via CD8-targeted lipid nanoparticles","volume":"32","author":"Billingsley","year":"2024","journal-title":"Molecular Therapy"},{"key":"10.1016\/bs.apha.2026.05.003_bib11","first-page":"189","article-title":"In vivo CAR T cell generation: Pharmacological principles and clinical translation","volume":"24","author":"Bot","year":"2025","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/bs.apha.2026.05.003_bib12","first-page":"45","article-title":"Clinical landscape of in vivo CAR T cell platforms","volume":"32","author":"Bot","year":"2026","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.apha.2026.05.003_bib13","first-page":"721","article-title":"In vivo hematopoietic stem cell engineering using fusogen-based lentiviral vectors","volume":"32","author":"Botchkarev","year":"2025","journal-title":"Cell Stem Cell"},{"issue":"2","key":"10.1016\/bs.apha.2026.05.003_bib14","first-page":"411","article-title":"Dasatinib enhances CD3-targeted lentiviral transduction of resting T cells by inhibiting CD3 internalization","volume":"31","author":"Braun","year":"2023","journal-title":"Molecular Therapy"},{"issue":"6656","key":"10.1016\/bs.apha.2026.05.003_bib15","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1126\/science.ade6967","article-title":"In vivo hematopoietic stem cell modification by mRNA delivery","volume":"381","author":"Breda","year":"2023","journal-title":"Science (New York, N. Y.)"},{"issue":"6","key":"10.1016\/bs.apha.2026.05.003_bib16","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: What we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"4","key":"10.1016\/bs.apha.2026.05.003_bib17","first-page":"932","article-title":"Disparities in CAR T-cell therapy access and utilization in the United States","volume":"8","author":"Ceja","year":"2024","journal-title":"Blood Advances"},{"issue":"11","key":"10.1016\/bs.apha.2026.05.003_bib18","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: Principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.003_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: The cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/bs.apha.2026.05.003_bib20","first-page":"1021","article-title":"Access to commercial CAR T-cell therapy: Barriers and solutions","volume":"43","author":"Chung","year":"2025","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.003_bib21","first-page":"54","article-title":"Tissue-resident T cells and the composition of secondary lymphoid organs","volume":"7","author":"Conde","year":"2022","journal-title":"npj Genomic Medicine"},{"issue":"8","key":"10.1016\/bs.apha.2026.05.003_bib22","first-page":"2254","article-title":"Stem cell memory T cell subsets show superior proliferative capacity in CAR T cell products and correlate with clinical outcome","volume":"106","author":"Denlinger","year":"2020","journal-title":"Haematologica"},{"issue":"18","key":"10.1016\/bs.apha.2026.05.003_bib23","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1016\/bs.apha.2026.05.003_bib24","first-page":"1392","article-title":"Antigen identification and application of vectored antibody gene delivery for in vivo CAR T cell generation","volume":"40","author":"Dobson","year":"2022","journal-title":"Nature Biotechnology"},{"issue":"7643","key":"10.1016\/bs.apha.2026.05.003_bib25","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"issue":"18","key":"10.1016\/bs.apha.2026.05.003_bib26","doi-asserted-by":"crossref","first-page":"7306","DOI":"10.1073\/pnas.1214441110","article-title":"LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus","volume":"110","author":"Finkelshtein","year":"2013","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"5","key":"10.1016\/bs.apha.2026.05.003_bib27","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nature Medicine"},{"issue":"19","key":"10.1016\/bs.apha.2026.05.003_bib28","first-page":"3174","article-title":"Combining T-cell-specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors","volume":"3","author":"Frank","year":"2019","journal-title":"Blood Advances"},{"issue":"18","key":"10.1016\/bs.apha.2026.05.003_bib29","first-page":"3462","article-title":"Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins","volume":"116","author":"Frecha","year":"2010","journal-title":"Blood"},{"key":"10.1016\/bs.apha.2026.05.003_bib30","first-page":"380","article-title":"Enhancing chimeric antigen receptor T cell anti-tumor function through advanced media design","volume":"24","author":"Ghassemi","year":"2022","journal-title":"Molecular Therapy Methods & Clinical Development"},{"issue":"3","key":"10.1016\/bs.apha.2026.05.003_bib31","first-page":"394","article-title":"Targeted in vivo gene editing via CRISPR-Cas9 enables endonuclease-assisted CAR T cell generation","volume":"42","author":"Hamilton","year":"2024","journal-title":"Nature Biotechnology"},{"issue":"9","key":"10.1016\/bs.apha.2026.05.003_bib32","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.15252\/emmm.201607485","article-title":"Clinical development of CAR T cells\u2014challenges and opportunities in translating innovative treatment concepts","volume":"9","author":"Hartmann","year":"2017","journal-title":"EMBO Molecular Medicine"},{"issue":"35","key":"10.1016\/bs.apha.2026.05.003_bib33","article-title":"Incorporating CD47 into the lentiviral envelope reduces phagocytic clearance and prolongs vector circulation time in vivo","volume":"8","author":"Ho","year":"2022","journal-title":"Science Advances"},{"issue":"12","key":"10.1016\/bs.apha.2026.05.003_bib34","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nature Reviews Materials"},{"key":"10.1016\/bs.apha.2026.05.003_bib35","first-page":"234","article-title":"Pharmacodynamic-guided dosing of CD8-targeted LNP-delivered CAR T cells","volume":"43","author":"Hunter","year":"2025","journal-title":"Nature Biotechnology"},{"key":"10.1016\/bs.apha.2026.05.003_bib36","article-title":"Biomaterial scaffold-based local delivery for in situ CAR T cell programming in solid tumors","volume":"308","author":"Inamdar","year":"2024","journal-title":"Biomaterials"},{"issue":"11","key":"10.1016\/bs.apha.2026.05.003_bib37","first-page":"1574","article-title":"Deconvolution of clinical variance in CAR-T cell pharmacology and response","volume":"41","author":"Kirouac","year":"2023","journal-title":"Nature Biotechnology"},{"issue":"27","key":"10.1016\/bs.apha.2026.05.003_bib38","doi-asserted-by":"crossref","first-page":"9571","DOI":"10.1073\/pnas.0503726102","article-title":"Central memory self\/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells","volume":"102","author":"Klebanoff","year":"2005","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.003_bib39","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nm.4015","article-title":"Prospects for gene-engineered T cell immunotherapy for solid cancers","volume":"22","author":"Klebanoff","year":"2016","journal-title":"Nature Medicine"},{"issue":"7950","key":"10.1016\/bs.apha.2026.05.003_bib40","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"Enhanced CAR T cell activity in solid tumors by vaccine boosting","volume":"615","author":"Labanieh","year":"2023","journal-title":"Nature"},{"issue":"7","key":"10.1016\/bs.apha.2026.05.003_bib41","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-020-0911-7","article-title":"IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies","volume":"26","author":"Leborgne","year":"2020","journal-title":"Nature Medicine"},{"issue":"6","key":"10.1016\/bs.apha.2026.05.003_bib42","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling in chimeric antigen receptor T cells","volume":"21","author":"Long","year":"2015","journal-title":"Nature Medicine"},{"issue":"5","key":"10.1016\/bs.apha.2026.05.003_bib43","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/bs.apha.2026.05.003_bib44","article-title":"Switchable CAR-T cells in advanced solid tumors","volume":"12","author":"Michels","year":"2023","journal-title":"eLife"},{"issue":"11","key":"10.1016\/bs.apha.2026.05.003_bib45","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.15252\/emmm.201708148","article-title":"Genome editing for scalable production of alloantigen-free lentiviral vectors for in vivo gene therapy","volume":"9","author":"Milani","year":"2017","journal-title":"EMBO Molecular Medicine"},{"key":"10.1016\/bs.apha.2026.05.003_bib46","first-page":"478","article-title":"Advances in lentiviral vector manufacturing for CAR T cell therapy","volume":"19","author":"Molnar","year":"2020","journal-title":"Molecular Therapy Methods & Clinical Development"},{"issue":"8","key":"10.1016\/bs.apha.2026.05.003_bib47","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1128\/JVI.03287-13","article-title":"Role of phosphatidylserine receptors in enveloped virus infection","volume":"88","author":"Morizono","year":"2014","journal-title":"Journal of Virology"},{"issue":"8","key":"10.1016\/bs.apha.2026.05.003_bib48","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease\u2014a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/bs.apha.2026.05.003_bib49","first-page":"1093","article-title":"Use of heterologous lentiviral pseudotypes reduces the risk of anti-vector humoral immunity following repeat administration","volume":"17","author":"Munis","year":"2019","journal-title":"Molecular Therapy Methods & Clinical Development"},{"issue":"4","key":"10.1016\/bs.apha.2026.05.003_bib50","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: A phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nature Medicine"},{"issue":"6","key":"10.1016\/bs.apha.2026.05.003_bib51","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41408-021-00508-1","article-title":"AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia","volume":"11","author":"Nawaz","year":"2021","journal-title":"Blood Cancer Journal"},{"issue":"26","key":"10.1016\/bs.apha.2026.05.003_bib52","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1016\/bs.apha.2026.05.003_bib53","first-page":"1947","article-title":"In vivo generation of CAR T cells in non-human primates using T cell-targeted lentiviral vectors","volume":"30","author":"Nicolai","year":"2024","journal-title":"Nature Medicine"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.003_bib54","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/s41467-018-03432-4","article-title":"Structural basis for the recognition of LDL-receptor family members by VSV glycoprotein","volume":"9","author":"Nikolic","year":"2018","journal-title":"Nature Communications"},{"key":"10.1016\/bs.apha.2026.05.003_bib55","first-page":"748","article-title":"In vivo CRISPR-mediated site-specific integration enables stable CAR T cell generation","volume":"391","author":"Nyberg","year":"2026","journal-title":"Science (New York, N. Y.)"},{"issue":"11","key":"10.1016\/bs.apha.2026.05.003_bib56","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809158","article-title":"In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome","volume":"10","author":"Pfeiffer","year":"2018","journal-title":"EMBO Molecular Medicine"},{"issue":"8","key":"10.1016\/bs.apha.2026.05.003_bib57","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1182\/blood-2018-01-828343","article-title":"Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL","volume":"132","author":"Rossi","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/bs.apha.2026.05.003_bib58","first-page":"483","article-title":"Low density lipoprotein receptor activity in human intracranial tumors and its relation to the cholesterol requirement of rapidly proliferating cells","volume":"50","author":"Rudling","year":"1990","journal-title":"Cancer Research"},{"issue":"6576","key":"10.1016\/bs.apha.2026.05.003_bib59","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science (New York, N. Y.)"},{"issue":"17","key":"10.1016\/bs.apha.2026.05.003_bib60","article-title":"Immunotropic lipid nanoparticles for selective in vivo mRNA delivery to immune cells","volume":"32","author":"Sanchez-Cano","year":"2022","journal-title":"Advanced Functional Materials"},{"issue":"35","key":"10.1016\/bs.apha.2026.05.003_bib61","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"44","key":"10.1016\/bs.apha.2026.05.003_bib62","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2308511120","article-title":"The total mass, number, and distribution of immune cells in the human body","volume":"120","author":"Sender","year":"2023","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/bs.apha.2026.05.003_bib63","first-page":"3420","article-title":"T cell-specific promoters enhance safety of in vivo lentiviral CAR gene delivery","volume":"32","author":"Shin","year":"2024","journal-title":"Molecular Therapy"},{"key":"10.1016\/bs.apha.2026.05.003_bib64","first-page":"312","article-title":"Overcoming restriction factors in resting T cells for in vivo lentiviral CAR gene delivery","volume":"27","author":"Shin","year":"2026","journal-title":"Nature Immunology"},{"key":"10.1016\/bs.apha.2026.05.003_bib65","article-title":"Molecular imaging of chimeric antigen receptor T cell therapy","volume":"8","author":"Simonetta","year":"2021","journal-title":"Frontiers in Medicine"},{"issue":"5","key":"10.1016\/bs.apha.2026.05.003_bib66","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41591-021-01326-5","article-title":"Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells","volume":"27","author":"Singh","year":"2021","journal-title":"Nature Medicine"},{"issue":"2","key":"10.1016\/bs.apha.2026.05.003_bib67","first-page":"145","article-title":"The entry of herpesviruses and complement evasion strategies","volume":"35","author":"Spear","year":"1995","journal-title":"Virus Research"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.003_bib68","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nbt.3104","article-title":"Biopolymer implants enhance the efficacy of adoptive T-cell therapy by locally delivering contractile signals to T cells","volume":"33","author":"Stephan","year":"2015","journal-title":"Nature Biotechnology"},{"issue":"12","key":"10.1016\/bs.apha.2026.05.003_bib69","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.addr.2011.06.017","article-title":"Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: Prediction and prevention","volume":"63","author":"Szebeni","year":"2011","journal-title":"Advanced Drug Delivery Reviews"},{"key":"10.1016\/bs.apha.2026.05.003_bib70","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-1-0716-0872-2_2","article-title":"Vaccination with messenger RNA: A promising alternative to DNA vaccination","volume":"2197","author":"Tombacz","year":"2021","journal-title":"Methods in Molecular Biology"},{"issue":"6220","key":"10.1016\/bs.apha.2026.05.003_bib71","doi-asserted-by":"crossref","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"Uhlen","year":"2015","journal-title":"Science (New York, N. Y. )"},{"key":"10.1016\/bs.apha.2026.05.003_bib72","first-page":"9328","article-title":"Multi-gene payload engineering of in vivo CAR T cells","volume":"15","author":"Uslu","year":"2025","journal-title":"Nature Communications"},{"issue":"6","key":"10.1016\/bs.apha.2026.05.003_bib73","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","article-title":"Immunogenicity of CAR T cells in cancer therapy","volume":"18","author":"Wagner","year":"2021","journal-title":"Nature Reviews Clinical Oncology"},{"key":"10.1016\/bs.apha.2026.05.003_bib74","first-page":"1987","article-title":"vivo CD8-targeted lipid nanoparticle-delivered CAR T cells for systemic lupus erythematosus","volume":"31","author":"Wang","year":"2025","journal-title":"Nature Medicine"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.003_bib75","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1038\/s41467-018-05096-6","article-title":"Engineering circular RNA for potent and stable translation in eukaryotic cells","volume":"9","author":"Wesselhoeft","year":"2018","journal-title":"Nature Communications"},{"key":"10.1016\/bs.apha.2026.05.003_bib76","first-page":"1124","article-title":"First-in-human clinical trial of in vivo lentiviral CAR T cell therapy in relapsed\/refractory multiple myeloma","volume":"31","author":"Xu","year":"2025","journal-title":"Nature Medicine"},{"issue":"11","key":"10.1016\/bs.apha.2026.05.003_bib77","first-page":"7782","article-title":"High-throughput barcoded screening identifies immunotropic lipid nanoparticles for in vivo T cell delivery","volume":"146","author":"Xue","year":"2024","journal-title":"Journal of the American Chemical Society"}],"container-title":["Advances in Pharmacology","Pharmacology of T-Cell Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054358926000323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054358926000323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T19:54:34Z","timestamp":1783540474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1054358926000323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9780443470387"],"references-count":77,"URL":"https:\/\/doi.org\/10.1016\/bs.apha.2026.05.003","relation":{},"ISSN":["1054-3589"],"issn-type":[{"value":"1054-3589","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}